Cue Biopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Cue Biopharma, Inc. (CUE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 2.90 million shares for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2025-11-12
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-09-30 was 2.90M shares, a 70.59% increase year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-06-30 was 48.80K shares, a 91.78% decline year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2024-09-30 was 1.70M shares, a 154545354.55% increase year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2024-06-30 was 593.80K shares, a 324.14% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month |
|---|---|---|---|
| 2025-09-30 | 2.90M shares 10-Q · filed 2025-11-12 | 2.95M shares derived: sum of 2 quarters · filed 2025-11-12 | 4.90M shares 10-Q · filed 2025-11-12 |
| 2025-06-30 | 48.80K shares 10-Q · filed 2025-08-12 | 1.94M shares 10-Q · filed 2025-08-12 | |
| 2024-09-30 | 1.70M shares 10-Q · filed 2025-11-12 | 2.29M shares derived: sum of 2 quarters · filed 2025-11-12 | 4.20M shares 10-Q · filed 2025-11-12 |
| 2024-06-30 | 593.80K shares 10-Q · filed 2025-08-12 | 2.46M shares 10-Q · filed 2025-08-12 | |
| 2023-09-30 | 1.10 shares 10-Q · filed 2024-11-14 | 140.00K shares derived: sum of 2 quarters · filed 2024-11-14 | 2.60M shares 10-Q · filed 2024-11-14 |
| 2023-06-30 | 140.00K shares 10-Q · filed 2024-08-14 | 1.46M shares 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |